p53 and cancer therapy: a double-edged sword

doi:10.1172/JCI7861

Review

. 1999 Aug;104(3):223-5.

doi: 10.1172/JCI7861.

p53 and cancer therapy: a double-edged sword

G McGill¹, D E Fisher

Affiliations

Affiliation

¹ Division of Pediatric Hematology/Oncology, Graduate Program in Biological and Biomedical Sciences, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 10430602
PMCID: PMC408427
DOI: 10.1172/JCI7861

Review

p53 and cancer therapy: a double-edged sword

G McGill et al. J Clin Invest. 1999 Aug.

. 1999 Aug;104(3):223-5.

doi: 10.1172/JCI7861.

Authors

G McGill¹, D E Fisher

Affiliation

¹ Division of Pediatric Hematology/Oncology, Graduate Program in Biological and Biomedical Sciences, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

PMID: 10430602
PMCID: PMC408427
DOI: 10.1172/JCI7861

No abstract available

PubMed Disclaimer

Comment on

Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Bunz F, et al. J Clin Invest. 1999 Aug;104(3):263-9. doi: 10.1172/JCI6863. J Clin Invest. 1999. PMID: 10430607 Free PMC article.

Cited by

Network pharmacology study to explore the multiple molecular mechanism of SH003 in the treatment of non-small cell lung cancer.
Lee K, Choi YJ, Lim HI, Cho KJ, Kang N, Ko SG. Lee K, et al. BMC Complement Med Ther. 2024 Feb 1;24(1):70. doi: 10.1186/s12906-024-04347-y. BMC Complement Med Ther. 2024. PMID: 38303001 Free PMC article.
NRF2 and p53: Januses in cancer?
Rotblat B, Melino G, Knight RA. Rotblat B, et al. Oncotarget. 2012 Nov;3(11):1272-83. doi: 10.18632/oncotarget.754. Oncotarget. 2012. PMID: 23174755 Free PMC article. Review.
[High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells].
Deng J, Pan T, Zhou G, Gao Y, Peng W, Wei W, Lü C. Deng J, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2023 Oct 20;43(10):1657-1664. doi: 10.12122/j.issn.1673-4254.2023.10.02. Nan Fang Yi Ke Da Xue Xue Bao. 2023. PMID: 37933640 Free PMC article. Chinese.
DRAM1 increases the secretion of PKM2-enriched EVs from hepatocytes to promote macrophage activation and disease progression in ALD.
Tan J, Zhang J, Wang M, Wang Y, Dong M, Ma X, Sun B, Liu S, Zhao Z, Chen L, Jin W, Liu K, Xin Y, Zhuang L. Tan J, et al. Mol Ther Nucleic Acids. 2021 Dec 11;27:375-389. doi: 10.1016/j.omtn.2021.12.017. eCollection 2022 Mar 8. Mol Ther Nucleic Acids. 2021. PMID: 35036051 Free PMC article.
Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D. Fedier A, et al. Br J Cancer. 2002 Oct 21;87(9):1027-33. doi: 10.1038/sj.bjc.6600599. Br J Cancer. 2002. PMID: 12434296 Free PMC article.

See all "Cited by" articles

References

1. Evan GI, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–128. - PubMed
1. Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–269. - PMC - PubMed
1. Graeber T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91. - PubMed
1. Schmaltz C, Harrigan P, Fisher DE. Regulation of proliferation/survival decision during tumor cell hypoxia. Mol Cell Biol. 1998;18:2845–2854. - PMC - PubMed
1. McGill G, Shimamura A, Bates R, Savage RE, Fisher DE. Loss of matrix adhesion leads to rapid transformation-selective apoptosis in fibroblasts. J Cell Biol. 1997;138:901–911. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Evan GI, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–128. - PubMed

[2] Evan GI, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–128. - PubMed

[3] Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–269. - PMC - PubMed

[4] Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–269. - PMC - PubMed

[5] Graeber T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91. - PubMed

[6] Graeber T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91. - PubMed

[7] Schmaltz C, Harrigan P, Fisher DE. Regulation of proliferation/survival decision during tumor cell hypoxia. Mol Cell Biol. 1998;18:2845–2854. - PMC - PubMed

[8] Schmaltz C, Harrigan P, Fisher DE. Regulation of proliferation/survival decision during tumor cell hypoxia. Mol Cell Biol. 1998;18:2845–2854. - PMC - PubMed

[9] McGill G, Shimamura A, Bates R, Savage RE, Fisher DE. Loss of matrix adhesion leads to rapid transformation-selective apoptosis in fibroblasts. J Cell Biol. 1997;138:901–911. - PMC - PubMed

[10] McGill G, Shimamura A, Bates R, Savage RE, Fisher DE. Loss of matrix adhesion leads to rapid transformation-selective apoptosis in fibroblasts. J Cell Biol. 1997;138:901–911. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

p53 and cancer therapy: a double-edged sword

Affiliation

p53 and cancer therapy: a double-edged sword

Authors

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous